Federal Court Dismisses HEC Pharm’s Damages Claim Over Novartis Gilenya Injunction

On Tuesday, a federal court in Delaware dismissed HEC Pharm Co.’s attempt to secure damages following a preliminary injunction that barred the company from launching a generic version of Novartis Pharmaceuticals’ multiple sclerosis medication, Gilenya. The court’s decision punctuates a series of legal maneuvers in the pharmaceutical industry regarding market access and patent rights. For more information, you can access the complete details here.